Treating crescentic glomerulonephritis by targeting macrophages

Kidney Int. 2022 Dec;102(6):1212-1214. doi: 10.1016/j.kint.2022.09.004.

Abstract

Macrophage accumulation in the kidney is associated with the progression of crescentic glomerulonephritis (GN) and is mostly derived from circulating monocytes. FROUNT, a C-C motif chemokine receptor 2 (CCR2)-interacted protein, which is strongly expressed in monocytes/macrophages, enhances macrophage infiltration through CCR2-mediated chemotaxis. In this issue of the journal, Toda et al. reported that disulfiram, an inhibitor of FROUNT, attenuates GN by inhibition of the FROUNT-CCR2 interaction and macrophage migration and activation, suggesting a potential therapeutic role for crescentic GN.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Chemotaxis
  • Glomerulonephritis* / drug therapy
  • Glomerulonephritis* / metabolism
  • Humans
  • Macrophages / metabolism
  • Monocytes / metabolism
  • Receptors, CCR2* / metabolism

Substances

  • Receptors, CCR2